Hematopoietic stem cell/bone transplantation HSCT

Leather HL. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient What every transplanter needs to know. Bone Marrow Transplant 2004 33 137-152. 

Gratwohl A, Baldomero H, Schmid 0 et al. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe a report of the EBMT activity survey 2003. Bone Marrow Transplant. 2005 36 575-590. 

Observations of metabolic cross-correction provided the rationale for cellular replacement, achieved primarily through allogeneic hematopoietic stem cell or bone transplantation (HSCT) (Prasad and Kurtzberg, 2008). More recently, the use of neural stem cells (NSC) implanted in the brain of patients with late-infantile neuronal ceroid lipofuscinosis has been contemplated (Pierret et al., 2008) but there are no reports as yet of its potential efficacy. Within the central nervous system there must be proper integration of donor cells, and differentiation into appropriate cell types. As specialized cell types within the nervous system elaborate neurotransmitters and are involved with conducting electrical impulses, functional differentiation may be a major hurdle for the neurodegenerative LSDs. 

HLA human leukocyte antigen HSCT hematopoietic stem cell transplantation hyper-CVAD high-dose methotrexate and cytarabine alternating with fractionated cyclophosphamide plus vincristine, doxorubicin, and dexamethasone IBMTR International Bone Marrow Transplant Registry IL-2 interleukin-2 MDS myelodysplastic syndrome MLL mixed lineage leukemia MUD matched unrelated donor NCCN National Comprehensive Cancer Network NST nonmyeloablative stem cell transplant OS overall survival Ph+ Philadelphia chromosome PML promyelocytic leukemia (gene)... 

Hematopoietic stem cell transplantation (HSCT) is a process that involves intravenous infusion of hematopoietic stem cells from a compatihle donor into a recipient, usually following administration of high-dose chemotherapy. Hematopoietic stem cells can be derived from the bone marrow, peripheral blood, or umbilical cord blood. The rationale for HSCT in the treatment of malignant disease is based on studies that show that most anticancer drugs have a steep... 

---